Regenxbio (RGNX) Return on Capital Employed (2015 - 2025)

Regenxbio's Return on Capital Employed history runs 11 years deep, the most recent figure standing at 43.45% for Q4 2025.

• On a quarterly basis, Return on Capital Employed rose 1648.0% year-over-year to 43.45% in Q4 2025; TTM through Dec 2025 was 43.45%, a 1648.0% increase from a year earlier, with the FY2025 full-year figure at 47.21%, up 877.0% from the prior year.
• Return on Capital Employed declined to 43.45% in Q4 2025 per RGNX's latest filing, from 36.15% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 19.35% in Q4 2021 and bottomed at 59.93% in Q4 2024.
• The 5-year median for Return on Capital Employed is 38.75% (2023), against an average of 30.47%.
• Across the five-year window, Return on Capital Employed soared 4277 bps in 2022 and plunged 6301 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 19.35% in 2021, then plunged by 287 bps to 36.1% in 2022, then plunged by 57 bps to 56.61% in 2023, then declined by 6 bps to 59.93% in 2024, then grew by 28 bps to 43.45% in 2025.
• Per Business Quant, the three latest RGNX Return on Capital Employed figures stand at 43.45% (Q4 2025), 36.15% (Q3 2025), and 39.52% (Q2 2025).